LianBio rises as Pfizer opts to develop co's RSV therapy

LianBio

19/12/2022 12:59

** Shares of China-focused biotech LianBio  LIAN.O  up ~50%
at $2.02 premarket- set for a near two-month high if gains hold
    ** Pfizer opts to develop and commercialize LianBio's
sisunatovir, a respiratory syncytial virus (RSV) therapeutic
candidate, in Mainland China, Hong Kong, Macau, and Singapore
    ** The deal is pursuant to the companies' existing strategic
collaboration to expand patient access to novel therapeutics in
Greater China
    ** LIAN will receive a $20 mln upfront payment which will be
released from previously restricted cash paid by PFE in 2020
under the existing strategic collaboration
    ** LIAN is eligible to receive up to $135 mln as milestone
payments and low single-digit percent of net sales in the
territories
    ** Stock down 78.1% YTD, as of last close
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))